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ABSTRACT 
 
Pregestational diabetes is highly associated with an increased risk of birth defects. 
However, factors that can increase or reduce the expressivity and penetrance of 
malformations in pregnancies in women with diabetes remain poorly identified. All-trans 
retinoic acid (RA) plays crucial roles in embryogenesis. Here, we find that Cyp26a1, 
which encodes a key enzyme for catabolic inactivation of RA required for tight control 
of local RA concentrations, is significantly downregulated in embryos of diabetic mice. 
Embryonic tissues expressing Cyp26a1 show reduced efficiency of RA clearance. 
Embryos exposed to diabetes are thus sensitized to RA and more vulnerable to the 
deleterious effects of increased RA signalling. Susceptibility to RA teratogenesis is 
further potentiated in embryos with a preexisting genetic defect of RA metabolism. 
Increasing RA clearance efficiency using a preconditioning approach can counteract the 
increased susceptibility to RA teratogenesis in embryos of diabetic mice. Our findings 
provide new insight into gene-environment interactions that influence individual risk in 
the manifestation of diabetes-related birth defects and shed light on the environmental 
risk factors and genetic variants for a stratified medicine approach to screening women 
with diabetes who are of childbearing age and assessing the risk of birth defects during 
pregnancy.  
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Offspring of women with pregestational diabetes show a markedly increased risk 
of birth defects (1). While the cause of diabetic embryopathy is known to be 
multifactorial, previous investigations focused mainly on the effect of maternal diabetes 
alone on the embryo. Genetic and environmental factors that can influence the 
expressivity and penetrance of congenital malformations in pregnancies in women with 
diabetes remain far from clear (2,3). Interestingly, some malformations found in the 
offspring of mothers with diabetes (4-6) are very similar to those anomalies arising from 
exposure to excess retinoids (vitamin A and its analogues) in humans and animals (7-9). 
For instance, a large-scale study of 18 population-based congenital anomaly registries 
shows that the odds ratio for caudal regression in pregnancies in women with versus 
without diabetes (odds ratio 26.4; 95% CI 8.98-77.64) is well above that of other 
malformations (4), which strengthens the conclusion of previous studies that caudal 
regression is a characteristic anomaly associated with pregnancy in women with diabetes 
(5,6). Caudal regression also commonly occurs with retinoid teratogenesis in animal 
studies (9-11).   
 Many of the functions of vitamin A in embryogenesis are mediated via its 
metabolite all-trans retinoic acid (RA), which is a key signaling molecule controlling the 
development of multiple organ systems. Different embryonic tissues/organs show 
variations in requirements for RA; thus tight regulation of local RA concentrations is 
critical to ensure the precise levels of RA signaling required for normal embryo 
development. An important mechanism to control local RA concentrations is via 
catabolic inactivation by the CYP26 enzymes belonging to the cytochrome P450 family. 
Three Cyp26 genes-namely Cyp26a1, Cyp26b1, and Cyp26c1-are expressed in specific 
embryonic tissues and attenuate the deleterious effects of excessive RA signalling. 
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Among them, CYP26A1 is the key RA catabolizing enzyme in many tissues and the only 
subtype that is expressed in the tailbud region of the embryo (12), where caudal 
regression arises (11). Homozygous deletion of Cyp26a1 in mice is lethal in mid- to late 
gestation, with embryos exhibiting caudal truncation (13,14). Similarly, we and others 
have demonstrated that mouse embryos exposed to excess RA develop caudal truncation 
and various phenotypes, including specific renal, anorectal, caudal spinal cord, and lower 
extremity malformations (10,11,15) commonly associated with caudal regression in 
humans (16,17). Moreover, we found that maternal diabetes potentiates the effect of RA 
to cause caudal regression in mice (18). This similarity in phenotypes resulting from 
genetic and environmental disturbances therefore led us to speculate that maternal 
diabetes may perturb embryonic CYP26A1 function in maintaining the tight regulation of 
local RA concentrations in specific tissues. We hypothesized that such tissues would be 
vulnerable to a perturbation of RA levels and exhibit increased susceptibility to RA 
teratogenesis. Here, we provide evidence to support this hypothesis using a mouse model 
of pregestational diabetes. Notably, our findings show that interaction between a genetic 
predisposition and an environmental agent to disrupt RA homeostasis can potentiate 
maternal diabetes-induced deregulated RA catabolism in increasing the risk for 
malformation.  
 
 5
RESEARCH DESIGN AND METHODS  
 
Animals  
All animal experimentation was conducted following the guidelines set by The Chinese 
University of Hong Kong. Diabetes was induced in female ICR mice by streptozotocin 
injections according to established protocols (18). Mice with a blood glucose 
concentration ≥16.7 mmol/L were classified as manifestly diabetic (MD). Untreated, 
age-matched female ICR mice were used as the nondiabetic (ND) control. Mice were 
kept in a 12-h light/12-h dark cycle; the light cycle commenced at 11:00 A.M. Pregnancies 
were obtained by timed mating for 2 h (9:00-11:00 A.M.) between MD/ND female ICR 
mice and male ICR mice, or male Cyp26a1+/- mice in a 129/C57BL/6Cr/DBA mixed 
background (a gift from Prof. Hamada [14]). The time of finding a copulation plug at 
11:00 A.M. was defined as embryonic day (E) 0. Mice were checked for blood glucose 
levels before embryo collection to confirm that MD mice remained diabetic during 
pregnancy (Supplementary Table 1). 
 
Gene Expression 
Whole embryos were subjected to in situ hybridization for Cyp26a1, Cyp26b1, or 
Cyp26c1 with digoxygenin-labeled RNA probes (19). The mRNA expression levels of 
various genes were determined using real-time quantitative RT-PCR. To minimize 
differences in expression levels resulting from variations in the developmental stage, only 
embryos within the same somite range (somite stage 9-10 for E8 embryos; somite stage 
19-21 for E9 embryos) in each litter were collected. This criterion was adopted for 
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embryo collection in other experiments. For crossing between male and female ICR mice, 
all embryos at the appropriate somite stage from the same litter were pooled as one 
sample. For crossing between male Cyp26a1+/- and female ICR mice, individual embryos 
were collected. After DNA genotyping of the yolk sac using PCR with primers as 
previously described (14), embryos of the same genotype (Cyp26a1+/+ or Cyp26a1+/-) 
from the same litter were pooled as one sample. Total RNA was extracted from the whole 
embryo or tailbud (defined as the caudal end of the embryo up to one somite length 
posterior to the last somite) samples using the FavorPrep Tissue Total RNA Mini Kit 
(Favorgen Biotech Corp.). An equal amount of RNA (250 ng) was reverse-transcribed 
into first-strand cDNA using a High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). The cDNA yielded from reverse transcription of 1.67 ng RNA was 
subjected to quantitative PCR using ABI 7900HT Fast Real-Time PCR system (Applied 
Biosystems), with SYBR Green PCR Master Mix (Applied Biosystems). β-actin was 
used as the internal control for normalization. The PCR conditions and primer sequences 
were listed in Supplementary Table 2.  
 
In Vitro RA Degrading Efficiency 
Using an assay modified from Yamamoto et al. (20), four tailbuds of E9 embryos from 
the same litter were pooled as one sample and lysed in 5 µL of DMEM by trituration with 
a pipette tip, followed by five cycles of freezing in liquid nitrogen and thawing in a water 
bath at 37oC for 1 min. The whole lysate was added to 50 µL of a reaction mixture 
containing 50 nmol/L all-trans RA (Sigma-Aldrich), with or without 1.6 mg/mL NADPH 
(a cofactor of the cytochrome P450 enzyme), 0.3 mg/mL dithiothreitol (DTT; a reducing 
agent for optimal cytochrome P450 enzyme function), and the CYP26-specific inhibitor 
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R115866 (21) at a concentration of 1, 10, or 100 nmol/L in a culture medium (DMEM 
supplemented with 10% FBS). The reaction mixture was then incubated in a 5% CO2 
incubator at 37oC for 2 h, during which the exogenous RA in the medium was degraded 
by the RA-catabolizing enzyme in the tailbud lysate. After incubation, the amount of RA 
remaining was determined by adding the reaction mixture, diluted 30-fold with the 
culture medium, in triplicate to a 96-well plate containing RA reporter cells, which are F9 
cells transfected with an RA response element that drives -galactosidase expression (22). 
Serially diluted RA standard solutions at concentrations from 10-6 to 10-11 mol/L were 
added in triplicate to the same 96-well plate. After culturing for 24 h, cells were stained 
with X-gal and the intensity of the blue product was measured using a microplate 
spectrophotometer. RA in the sample was quantified using a standard curve constructed 
with the serially diluted RA solutions (Supplementary Fig. 1). 
 
In Vivo Clearance of RA 
To determine the in vivo efficiency of RA clearance, the tailbud was collected under dim 
yellow light at various time points after injection of RA (50 mg/kg body weight) at E9,  
Tailbuds were individually placed in 300 µL of the culture medium, with 100 nmol/L 
R115866 added to inhibit endogenous CYP26 enzymes. After 24 h of incubation in 5% 
CO2 at 37oC to allow maximum release of RA from the tailbud into the medium, RA in 
the medium was quantified using the RA reporter cell line. A preliminary study 
demonstrated that the culture conditions did not cause significant degradation of RA 
(Supplementary Fig. 2). To validate that RA measurements using the RA reporter cell 
line indeed measure RA released from tissues that can modulate RA levels, the tailbuds 
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of E9 embryos were collected 3 h after injection of RA. The midbrain, which does not 
express any Cyp26 genes in untreated or RA-treated conditions, was also collected from 
these embryos as a control. Tissues from the same litter were pooled as one sample. RA 
in the sample was quantified using high-performance liquid chromatography (23). 
 
Detection of Bioactive RA in Tailbuds 
The caudal-most portion of the tailbuds of E9 embryos of MD and ND mice was excised 
under dim yellow light and individually placed on top of RA reporter cells grown on a 
96-well plate in the culture medium, with 100 nmol/L R115866 added to inhibit 
endogenous CYP26 enzymes. After 24 h of culture, cells were stained with X-gal. The 
number of positively stained cells around the tailbud explant was counted under a 
stereomicroscope.    
 
Susceptibility to RA Teratogenesis 
The teratogenic effect of RA is dose- and stage-dependent (9). To determine 
susceptibility to RA teratogenesis, MD or ND mice at E8 or E9 received an 
intraperitoneal injection of 25 mg/kg RA or an equivalent volume of suspension vehicle 
(peanut oil) as a control, and their embryos were examined at E13. Embryos treated with 
RA at E9 were examined for the extent of caudal truncation, which was expressed as the 
ratio of tail length (TL) to crown-rump length (CRL), as used in our previous studies 
(18). Embryos treated with RA at E8 were examined for exencephaly and spina bifida. 
Near-term E18 fetuses from MD or ND mice injected with 40 mg/kg RA at E9 were 
examined for various renal malformations, as described in our previous studies (24). 
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Maternal preconditioning with low-dose RA (0.625 or 1.25 mg/kg) or suspension vehicle 
(peanut oil) as a control was achieved by oral gavage 2 h before administering an 
intraperitoneal injection of a teratogenic dose of RA.  
 
Statistics 
Statistical differences between two groups were analyzed by the unpaired Student t test. 
Differences between multiple groups of data were analysed using one-way ANOVA, 
followed by the Bonferroni post hoc test, or using the contrast test to assess the extent of 
differences. Dose response was analyzed using linear regression. The best-fit curves were 
compared using nonlinear regression. Data were presented as mean ± SEM, with P < 0.05 
considered as statistically significant. All statistical analyses were conducted using SPSS 
software (SPSS Inc.), except nonlinear regression analysis, which was conducted using 
Prism software (GraphPad Software). 
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RESULTS 
 
Cyp26a1 Expression Levels and RA Degrading Efficiency Are Reduced in Embryos 
of Diabetic Mice 
During early mouse postimplantation development, Cyp26a1 is initially expressed in the 
headfold mesenchyme (Fig. 1A), and then extends to the caudal neural plate and 
primitive streak (Fig. 1B). As development proceeds, Cyp26a1 expression persists at the 
caudal end (Fig. 1C and D), now called the tailbud, which contains progenitor cells for 
forming various posterior structures. Rostrally, it is expressed in the craniofacial, 
cervical, and branchial arch mesenchyme (Fig. 1C). Embryos of MD mice exhibit a 
significant decrease in Cyp26a1 mRNA transcripts in all of these regions compared with 
embryos of ND mice (Fig. 1A-E). In contrast, Cyp26b1 and Cyp26c1 are expressed 
predominantly in the cranial region but not in the tailbud (Fig. 1F and H), and show no 
significant difference in expression levels between embryos of MD and ND mice (Fig. 
1G and I). 
To determine whether a decrease in Cyp26a1 expression results in reduced 
efficiency of RA catabolism, we used an in vitro assay to compare the RA-degrading 
efficiency of the tailbud, which exclusively expresses Cyp26a1, but not Cyp26b1 and 
Cyp26c1, from E9 embryos of MD and ND mice. Results showed that only a low level 
of RA-degrading activity was detected when tailbud lysate alone was applied (Fig. 2A). 
However, in the presence of NADPH and DTT for optimal activity of CYP26 enzymes, 
66% of added RA was degraded within 2 h. In contrast, cotreatment with 1-100 nmol/L 
of R115866, a potent CYP26-specific inhibitor (21), resulted in significant 
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dose-dependent inhibition of RA degradation. Notably, while there was no significant 
difference in the protein content of the tailbuds excised from embryos of MD and ND 
mice (Supplementary Fig. 3), tailbud lysate of the MD group exhibited only 45% of the 
activity of the ND group.  
To further compare the efficiency of in vivo clearance of RA, MD and ND mice 
were injected with an exogenous dose of RA (50 mg/kg) at E9; then RA in individual 
tailbuds was measured at hourly intervals using the RA reporter cell line (Fig. 2B), 
which showed results comparable with those from quantification of RA using 
high-performance liquid chromatography (Supplementary Table 3). Despite a similar 
response time course in the MD and ND groups, the amount of RA in tailbuds of the MD 
group was significantly higher than in the ND group at all time points studied (Fig. 2B). 
Moreover, by determining the area under the concentration-time curve (AUC), which is 
considered as the most appropriate pharmacokinetic correlate of embryotoxicity of RA 
(25), there was a twofold difference between the MD (AUC0-8h: 25.59 nmol/L X h, 
calculated using Prism 5 software [GraphPad Software]) and the ND (AUC0-8h: 12.70 
nmol/L X h) groups, implying that the efficiency of in vivo RA clearance in tailbuds of 
embryos exposed to diabetes was reduced by 50%. By contrast, the E9 midbrain, which 
does not express any of the three Cyp26 genes in both untreated and RA-treated 
conditions (Supplementary Fig. 4A), exhibited no difference in RA levels between 
embryos of MD and ND mice at 3 h after the injection of RA (Supplementary Fig. 4B).  
 
RA Levels Are Increased in Tailbuds of Embryos of Diabetic Mice 
To determine whether reduction in RA-degrading efficiency would lead to an increase in 
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endogenous RA levels, we excised the caudal-most portion of the tailbud (Fig. 3A) 
farthest from the RA source in adjacent trunk tissues, and put it directly on the RA 
reporter cells to detect bioactive RA release (22). Reporter cells exposed to RA expressed 
β-galactosidase and turned blue with X-gal staining. There were hardly any positively 
stained cells around tailbuds from embryos of ND mice (Fig. 3B and C), which agrees 
with previous findings that the tailbud is normally devoid of RA (26). However, stained 
cells were observed around more than half the tailbuds from embryos of MD mice. The 
number of stained cells varied from fewer than 10 to more than 40, implying a varying 
magnitude of elevation of RA level in tailbuds of embryos exposed to diabetes. 
Several genes including Fgf8, Wnt3a, and Cdx2, are indispensable key players in 
caudal development (27). Excessive RA has been demonstrated to downregulate these 
genes and cause axial truncation (11,26,28). Of these genes, however, only Fgf8 was 
significantly downregulated in the tailbuds of embryos of MD mice (Fig. 4A). It is 
possible that the magnitude of increase in RA levels may not have reached the threshold 
for causing a detectable alteration in the expression of some of these genes. We therefore 
challenged embryos with 50 mg/kg of RA to test whether deregulated catabolism of RA 
would sensitize embryos of MD mice to RA. A dramatic increase in mRNA levels of 
Cyp26a1 in the tailbud occurred 4 h after injection of RA (Fig. 4B), showing that 
Cyp26a1 is highly inducible by RA. However, the magnitude of upregulation of Cyp26a1 
in tailbuds of the MD group was significantly less than that in the ND group (P < 0.05, 
contrast test), which further exacerbated the difference between these two groups. 
Concomitantly, there was a marked downregulation of Fgf8, with expression levels in 
tailbuds of the RA-treated MD group reduced to less than one-third of that in the ND 
group without RA treatment (Fig. 4C). Consistent with our previous findings (18), though 
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there was no difference in Wnt3a expression levels between the tailbuds of MD and ND 
groups at a steady state (Fig. 4A), upon RA challenge Wnt3a was downregulated to a 
significantly greater extent in tailbuds of the MD group than those of the ND group (Fig. 
4C). Similarly, the MD group showed an increased propensity toward RA-induced 
downregulation of Cdx2. 
RA action is mediated via transactivation by retinoic acid receptors (RARs) that 
heterodimerize with retinoid X receptors (RXRs). In the mouse embryo, Rarγ and Rxrα 
mediate the teratogenic effect of RA in inducing caudal truncation (29,30). However, 
there were no differences in expression levels of Rarγ and Rxrα between the tailbuds of 
embryos of ND and MD mice at a steady state (Fig. 4A) or 4 h after injection of RA (Fig. 
4C). Together, these findings support the idea that enhanced downregulation of caudal 
regulatory genes in the tailbuds of embryos of MD mice is due to increased RA levels 
resulting from the reduced efficiency of RA degradation, rather than secondary to 
differences in the efficiency of transactivation via RA nuclear receptors.  
 
Genetic Reduction of Cyp26a1 Exacerbates the Susceptibility of Embryos of 
Diabetic Mice to RA Teratogenesis 
We asked whether a decrease in Cyp26a1 expression leads directly to reduced efficiency 
of RA clearance, and whether functional loss of Cyp26a1 could interact with the maternal 
diabetic environment to influence RA-degrading efficiency and susceptibility to RA 
teratogenesis. To investigate these questions, we crossed Cyp26a1+/- male mice with MD 
or ND female mice. We hypothesized that Cyp26a1+/- mutant embryos would exhibit a 
lower RA-degrading efficiency than their Cyp26a1+/+ wild-type littermates and that 
exposure to maternal diabetes would exacerbate these genetic differences.  
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 Indeed, E9 embryos from different genotype-maternal environment combinations 
showed prominent differences in Cyp26a1 levels (Fig. 5A). The Cyp26a1 mRNA levels 
in tailbuds of Cyp26a1+/- embryos of MD mice were reduced to half of the level in 
Cyp26a1+/+ embryos of ND mice (Fig. 5B), with a corresponding decrease in 
CYP26-mediated RA-degrading efficiency (Fig. 5C). When RA levels were increased 
via maternal challenge with 25 mg/kg of RA, a 50% reduction in Cyp26a1 expression 
levels and RA-degrading efficiency in tailbuds of Cyp26a1+/- embryos of MD mice 
resulted in exposure to an eightfold higher effective concentration of RA in comparison 
with tailbuds of Cyp26a1+/+ embryos of ND mice (Fig. 5D). This effect was noted 3 h 
after RA injection, when accumulation of RA had reached its peak (Fig. 2B). In 
agreement with these findings, Cyp26a1+/- embryos of MD mice were most sensitized to 
RA-induced caudal truncation (Supplementary Fig. 5), as indicated by the smallest ratio 
of TL to CRL (Fig. 5E). The TL-to-CRL ratio was used as a “surrogate” both for the 
regression of multiple caudal structures in mice and for the analogous “caudal regression” 
process that affects species without tails, such as humans. In addition to caudal truncation, 
renal malformations are commonly associated with caudal regression (15,16). Indeed, we 
also found a 12-fold increase in the incidence (Fig. 5F) and severity (Table 1) of renal 
malformations in near-term Cyp26a1+/- fetuses exposed to maternal diabetes compared 
with wild-type fetuses in pregnancies in nondiabetic mice when challenged with a 
teratogenic dose of RA. 
 
Enhancing RA-Degrading Efficiency Counteracts the Increased Susceptibility to RA 
Teratogenesis Induced by Maternal Diabetes 
Cyp26a1 is highly RA-inducible, as it contains multiple RA response elements (31). Thus, 
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as a proof of principle, we attempted to “pre-condition” embryos of MD mice using an 
exogenous subteratogenic RA dose to upregulate Cyp26a1 expression in order to 
determine whether preconditioning could lead to a protective effect against RA 
teratogenesis. Previous findings showed that maternal oral administration of 2.5 mg/kg 
RA is sufficient to achieve near full rescue of midgestation mouse embryos lacking 
Raldh2, the principal RA synthetic enzyme (32). Therefore, we preconditioned pregnant 
mice with 0.625 or 1.25 mg/kg RA via oral feeding. These doses are far lower than the 
teratogenic range but yielded a dose-dependent increase in Cyp26a1 mRNA levels in 
tailbuds of embryos by 2 h after administration (Fig. 6A). Notably, supplementation with 
0.625 mg/kg RA did not induce changes in Fgf8, Wnt3a, and Cdx2 expression 
(Supplementary Fig. 6), but upregulated the expression of Cyp26a1 in tailbuds of the MD 
group to a level similar to that of the ND group fed the vehicle (Fig. 6A), with a 
concomitant normalization of RA-degrading efficiency (Fig. 6B). Then, when mothers 
were challenged with an intraperitoneal injection of a teratogenic dose of RA (25 mg/kg), 
we found the severity of caudal truncation to be significantly reduced, as shown by the 
significantly higher TL-to-CRL ratio in embryos of RA-preconditioned mice than in 
embryos from vehicle-fed mice in both the MD and ND conditions (Fig. 6C). Even the 
higher pre-conditioning dose of RA (1.25 mg/kg) was nonteratogenic and by itself did 
not affect the TL-to-CRL ratio of the embryo. While it could have had other effects on 
the embryo, in addition to upregulating Cyp26a1, the highly comparable pattern of 
dose-dependent upregulation of Cyp26a1 and dose-dependent increase in the TL-to-CRL 
ratio, in the absence of changes in the key caudal regulatory genes suggests a specific 
effect of preconditioning. These findings support the idea that preconditioning the 
embryo by enhancing RA-degrading efficiency can offer a protective effect against RA 
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teratogenesis and abolish the increased propensity of embryos from pregnancy in diabetic 
mice toward RA-induced caudal truncation.  
 Amongst the most frequent congenital anomalies associated with maternal 
diabetes are neural tube defects (NTDs) (4). Expression levels of Cyp26a1 in the cranial 
mesenchyme and the caudal neural plate are prominently reduced in E8 embryos of MD 
mice (Fig. 1B). Moreover, Cyp26a1-/- embryos exhibit exencephaly and spina bifida 
(13,14), suggesting the importance of the CYP26A1 enzyme in protecting these tissues 
from the deleterious effects of ectopic RA signaling. We found that injection of 25 mg/kg 
of RA at E8 induced around 6.7% exencephaly (Fig. 7A) and 4.4% spina bifida (Fig. 7B) 
in Cyp26a1+/+ embryos of ND mice. However, the incidence of RA-induced exencephaly 
and spina bifida was markedly increased by six- and sevenfold, respectively, in 
Cyp26a1+/+ embryos exposed to diabetes. A similar trend was found in embryos with an 
ICR X ICR background (Supplementary Fig. 7). The penetrance of NTDs was further 
exacerbated to 75.0% exencephaly and 71.3% spina bifida in Cyp26a1+/- embryos of MD 
mice with a preexisting genetic defect of RA catabolism. Similar to caudal truncation, the 
increase in susceptibility to RA-induced exencephaly and spina bifida caused by maternal 
diabetes was significantly reduced when embryos were preconditioned by maternal 
feeding of low-dose RA. Together, these findings support the idea that deregulated RA 
catabolism resulting from reduced levels of Cyp26a1 expression acts to sensitize 
embryos of mothers with diabetes to fluctuations in RA levels.  
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DISCUSSION 
 
In the present study, we found that the embryonic expression of the key RA-catabolizing 
enzyme Cyp26a1 is significantly downregulated under the condition of maternal diabetes. 
This leads to a decrease in RA inactivation efficiency and enhances the deleterious effect 
of excessive RA signaling on key caudal regulatory genes, such as Fgf8, Wnt3a, and 
Cdx2, which are required for continued axial elongation (27). We previously 
demonstrated that enhanced RA-induced downregulation of Wnt3a exacerbated apoptosis 
in the tailbud of mouse embryos exposed to a diabetic or hyperglycemic condition, 
leading to premature termination of caudal development (18,33). This resulted in the 
absence of lower vertebrae, an imperforate anus, clubfeet, and renal and caudal spinal 
cord malformations, all of which are commonly associated with caudal regression 
(10,11,15-17).     
The most frequent anomalies in pregnancies complicated by pregestational 
diabetes are NTDs and congenital heart defects (CHDs) (4,5). Results of this study 
support the idea that a decrease in Cyp26a1 expression also significantly increases the 
propensity of embryos from pregnancies in mothers with diabetes toward exencephaly 
and spina bifida when RA homeostasis is perturbed. Although we have not examined 
heart development, Cyp26a1 is expressed in cardiac neural crest cells and in the primitive 
heart tube and outflow tract, and Cyp26a1-/- embryos exhibit CHDs (13,14). Specific 
subgroups of CHD associated with improper RA signaling (8,9) are highly similar to 
those showing increased frequencies in the offspring of mothers with pregestational 
diabetes (4,34). As tight regulation of RA signaling is critical for many developmental 
processes, deregulated RA catabolism in early embryonic life can perturb the 
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development of multiple organ systems, which is in line with the finding that specific 
multiple congenital anomalies are common in affected offspring of mothers with 
pregestational diabetes (4,5). 
In our colony of diabetic mice, around 5% of embryos developed NTDs. However, 
large variations in congenital malformation frequencies occur between different 
laboratories; the frequency of NTDs reaches over 50% in some reports (35). While 
genetic background affects the susceptibility to diabetic embryopathy (2,36), recent 
studies demonstrate that different types of rodent chow could significantly alter the 
frequency of NTDs in embryos of diabetic mice, which supports the idea that maternal 
diet is an important modifier of the penetrance of malformation (3). Individual risk of 
malformation therefore depends on the interaction between genetic and environmental 
influences, which affects the developmental threshold of gene expression for normal 
development.  
Many genetic and environmental factors can affect embryonic RA homeostasis 
and signaling pathways to potentiate the effect of maternal diabetes in increasing 
malformation risk in the offspring. In humans, genetic polymorphisms of CYP26A1 that 
exhibit significantly lower degrading efficiency of RA have been identified (37,38). 
Duplication and polymorphisms of the human ALDH1A2 gene (encoding the principal 
RA synthetic enzyme during embryogenesis) are associated with an increase in serum RA 
levels (39) and various types of congenital anomalies, including CHDs and NTDs (40). 
Therefore common genetic variants involved in RA metabolism and signaling pathways 
could potentially be used as markers to identify pregnancies with increased malformation 
risk in mothers with diabetes. 
Retinoids are recognized human teratogens (41). Various forms of retinoids are in 
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clinical use or under study for treating a variety of diseases, including skin disorders, 
obesity, diabetes, and related complications (42). A well-known example is isotretinoin 
(13-cis RA), which is prescribed for the treatment of severe acne. It has been shown that 
the teratogenic threshold for isotretinoin is much lower in humans (0.5 mg/kg) (43) than 
in mice (100 mg/kg) (44). Human embryos are highly sensitive to isotretinoin, with a 
pattern of malformations (8) similar to that seen in animals exposed to excess all-trans 
RA (9). In fact, the teratogenic effect of 13-cis RA has been demonstrated in animals and 
suggested to be mediated in humans via its conversion to all-trans RA, which then binds 
to nuclear RA receptors to regulate gene expression (45). Moreover, our previous studies 
(18) and the present report show that maternal diabetes can enhance RA teratogenicity. 
Thus the teratogenic threshold for isotretinoin in embryos of women with pregestational 
diabetes may be even lower than the 0.5 mg/kg threshold previously quoted (43).  
Other than direct exposure to retinoids, medications such as valproic acid, an 
anticonvulsant, and fluconazole, used for treating fungal and yeast infections, have been 
shown to increase embryonic RA levels and induce malformations (46,47). Maternal 
smoking may also impose an increased risk; recent studies suggest that the teratogenic 
effect of nicotine on embryonic development is highly associated with suppression of 
Cyp26a1 and perturbation of RA signaling (48). In fact, many chemicals can modulate 
RA homeostasis. As such, NTDs and axial defects mediated by the modulation of RA 
homeostasis are proposed to be adopted as an adverse Outcome Pathway (AOP) 
framework for assessing the developmental toxicity of chemicals (49).   
There is a global trend that type 2 diabetes increasingly affecting children and 
adolescents (50). As the prevalence of diabetes among women of childbearing age 
continues to rise, the number of pregnancies complicated by pregestational diabetes is 
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likely to increase exponentially. The partial penetrance and variable expressivity of 
diabetic embryopathy underscore its multifactorial nature, implicating interactions 
between the genetic makeup of the embryo, maternal factors, and environmental 
influence. It is therefore of the utmost importance to identify risk factors in order to 
reduce malformations in pregnancy in women with diabetes. This study is, to our 
knowledge, the first to show that RA catabolism is deregulated in embryos exposed to 
diabetes and suggests that pregnancies in women with diabetes may be more vulnerable 
to perturbation in RA homeostasis and signaling. This may highlight the need to be 
cautious in assessing the upper safe levels of drugs, supplements, and potential 
teratogens-particularly those that have effects on RA homeostasis and signaling-for 
women with pregestational diabetes. Association studies should be conducted to 
determine whether specific genetic variants or periconceptional exposure to 
environmental agents that perturb RA homeostasis and signaling could be potentiation 
factors that increase individual malformation risk in the offspring of mothers with 
diabetes. Identifying these targets could contribute to genetic screening and preventive 
health care for women with diabetes with childbearing potential. Furthermore, as a proof 
of principle, we demonstrated the protective effect of correcting RA catabolism in 
embryos of diabetic mice. This finding may form the basis for developing stratified 
medicine to reduce the risk of congenital anomalies in pregnancies complicated by 
pregestational diabetes. 
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Table 1 - Frequency of various phenotypes (categorized according to the severity of 
malformations) induced by in vivo challenge with 40 mg/kg RA at E9 in Cyp26a1 
heterozygous null (+/-) and wild-type (+/+) fetuses from ND and MD mice at E18 
 
 Fetuses from 
ND mothers 
(n = 11 litters) 
Fetuses from 
MD mothers 
(n = 11 litters) 
Genotype +/+  +/- +/+ +/- 
Live fetuses (n) 68 61 48 49 
Fetuses with two normal kidneys (%) 91.2 80.3 62.5 36.7 
Nonagenesis renal malformation (%)  
  Unilateral (with a normal contralateral kidney) 
 
2.9 
 
9.8 
 
16.7 
 
26.5 
  Bilateral 2.9 8.2 12.5 10.2 
Renal agenesis (%)     
  Unilateral 
The solitary kidney is normal  
The solitary kidney has nonagenesis malformations 
 
1.5 
1.5 
 
1.6 
0 
 
0 
4.2 
 
8.2 
6.1 
Bilateral 0 0 4.2 12.2 
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FIGURE LEGENDS 
 
Figure 1 - Embryos of diabetic mice exhibit specific downregulation of Cyp26a1. A-D, F, 
and H: Whole-mount in situ hybridization patterns of Cyp26 genes in embryos of MD 
mice compared with those of ND mice. Cyp26a1 mRNA transcripts are seen in 
extraembryonic endoderm (red arrowhead) and headfold mesenchyme (yellow arrowhead) 
of E7 conceptuses (A); cranial mesenchyme (green arrowhead) and caudal neural plate 
(orange arrowhead) of E8 embryos (B); craniofacial, cervical, and branchial arch 
mesenchyme (circled) (C); and tailbud (blue arrowhead) of E9 embryos (D). Cyp26b1 (F) 
and Cyp26c1 (H) are expressed in the cranial but not in the tailbud region of E9 embryos. 
At least 20 embryos from five or six litters were examined for each group. Scale bar = 
0.05 mm (A), 0.1 mm (B), 0.7 mm (C), 0.2 mm (D), 0.7 mm for the whole embryo and 
0.35 mm for the caudal region (F and H). E,G, and I: Quantification of mRNA levels of 
Cyp26a1 (E), Cyp26b1 (G), and Cyp26c1 (I), normalized to β-actin and expressed 
relative to ND, which was set as 1 (n = 5 from five litters). *P < 0.05, Student t test. Error 
bars represent the mean ± SEM. 
 
Figure 2 - Embryos of diabetic mice show reduced efficiency of RA catabolism. A: In 
vitro RA-degrading efficiency, presented as the percentage of RA in the medium being 
degraded by the tailbud lysate, in the presence or absence of the cofactor (NADPH) and 
the reducing agent (DTT) for optimal activity of CYP26 enzymes, and varying 
concentrations of R115866 (CYP26 inhibitor) (n = 18 in ND and MD groups with 
NADPH-DTT; n = 3-9 in other groups from 20 ND and 18 MD litters). *P < 0.001, 
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Student t test; 
†
R2 = 0.742 and P = 0.001, linear regression. B: In vivo RA clearance 
measured as the amount of RA released from individual tailbuds, using a RA reporter cell 
line, at hourly intervals after injection of 50 mg/kg RA at E9 (n = 16-42 from three to 
eight litters). *P < 0.001 vs ND, Student t test and nonlinear regression. Error bars 
represent the mean ± SEM. 
 
Figure 3 – Increased levels of endogenous RA are detected in tailbuds of E9 embryos of 
diabetic mice using a RA reporter cell line. A: Image illustrates the caudal-most portion of 
the tailbud (boundary marked by the dotted line) as excised for detection of bioactive RA. 
B: Percentage of tailbuds excised from embryos of ND and MD mice that have different 
numbers of positively stained cells induced in the RA reporter cell line (n = 19 for ND 
and 22 for MD from three and four litters, respectively). C: Representative images of 
excised tailbuds that were placed directly on the RA reporter cells and have different 
numbers of stained cells induced in the RA reporter cell line. The amount of stained cells 
is categorized as (-), (+), (++) and (+++) as defined in B.   
 
Figure 4 - Tailbuds of E9 embryos of diabetic mice exhibit a greater magnitude of 
suppression of key genes for caudal development induced by RA. A: Quantification of 
mRNA levels of various caudal regulatory genes and RA nuclear receptors, normalized to 
β-actin and expressed relative to ND, which was set as 1, in tailbuds of embryos of ND 
and MD mice at E9 (n = 5 from five litters). **P < 0.01, Student t test. B and C: 
Quantification of mRNA levels of Cyp26a1 (B), and various caudal regulatory genes and 
RA nuclear receptors (C), normalized to β-actin and expressed relative to ND (CON), 
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which was set as 1, in tailbuds of embryos of ND and MD mice 4 h after injection of 50 
mg/kg RA (50RA) or vehicle as control (CON) into the mothers at E9 (n = 5 from five 
litters). *P < 0.05; **P < 0.01; ***P < 0.001, one-way ANOVA followed by the Bonferroni 
test. Error bars represent the mean ± SEM. 
 
Figure 5 - Cyp26a1 loss-of-function genotype interacts with diabetic maternal 
environment to influence RA-degrading efficiency and susceptibility to RA teratogenesis. 
A: Whole-mount in situ hybridization patterns of Cyp26a1 expression in Cyp26a1 
heterozygous null (+/-) embryos and their wild-type (+/+) littermates from ND and MD 
mice at E9. At least 30 embryos from six to eight litters were examined for each group. 
Scale bar = 0.25 mm. B: Quantification of Cyp26a1 mRNA, normalized to β-actin and 
expressed relative to ND (+/+), which was set as 1, in tailbuds of embryos from different 
genotype-maternal environment combinations at E9 (n = 5 from five litters). C: In vitro 
RA-degrading efficiency, presented as the percentage of RA in the medium being 
degraded by the tailbud lysate in the absence or presence of 100 nmol/L R115866 (a 
CYP26 inhibitor) (n = 8-13 from 10 to 14 litters). D: Quantification of RA released from 
individual tailbuds, using a RA reporter cell line, 3 h after in vivo challenge with 25 
mg/kg RA (25RA) at E9 (n = 22-28 from six to seven litters). E: Maternal injection of 
25RA or vehicle as the control (CON) at E9. Caudal truncation, measured in terms of the 
ratio of TL to CRL (TL/CRL), was examined in E13 embryos (n = 41-62 from 10 litters). 
F: Maternal injection of 40 mg/kg RA (40RA) or CON at E9. Near-term E18 fetuses were 
examined for renal malformations (n = 11 litters). *P < 0.05; **P < 0.01; ***P < 0.001, 
one-way ANOVA followed by the Bonferroni test. Error bars represent the mean ± SEM. 
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Figure 6 - Preconditioning with low-dose RA up-regulates Cyp26a1, increases 
RA-degrading efficiency, and protects against RA-induced caudal truncation. A: 
Quantification of Cyp26a1 mRNA, normalized to β-actin and expressed relative to ND 
(control [CON]), which was set as 1, in tailbuds of E9 embryos from ND and MD mice 2 
h after maternal oral feeding with low-dose RA (0.625 mg/kg [0.625RA] or 1.25 mg/kg 
[1.25RA]), or with vehicle as the control (n = 5 from five litters). B: In vitro 
RA-degrading efficiency, presented as the percentage of RA in the medium being 
degraded by the tailbud lysate from embryos with or without preconditioned with 
0.625RA (n = 5 from three to five litters). C: Embryos, preconditioned with low-dose RA 
or not, were maternally challenged with a teratogenic dose of 25 mg/kg RA (25RA) via 
administration to the mother at E9, and were examined for caudal truncation, measured in 
terms of the ratio of TL to CRL (TL/CRL) at E13 (n = 34-60 from three to five litters). *P 
< 0.01; **P < 0.001, Student t test. 
†
R2 = 0.900 and P < 0.001; 
††
R2 = 0.869 and P < 0.001; 
†††
R2 = 0.610 and P < 0.001; 
††††
R2 = 0.729 and P < 0.001, linear regression. The dotted 
lines represent no significant difference between the two groups. Error bars represent the 
mean ± SEM. 
 
Figure 7 - Increased susceptibility of embryos of diabetic mice to RA-induced NTDs is 
abolished by preconditioning with low-dose RA. A and B: Incidence rates of exencephaly 
(A) and spina bifida (B) in E13 Cyp26a1 heterozygous null (+/-) and wild-type (+/+) 
embryos from ND and MD mice (n = 8-9 litters). Effect of preconditioning by oral 
feeding of low-dose RA (0.625 mg/kg [0.625RA]) is compared with the vehicle-fed 
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control (CON) or no treatment (NT) groups, 2 h before in vivo challenge with a 
teratogenic dose of 25 mg/kg RA (25RA) at E8. *P < 0.05; **P < 0.01; ***P < 0.001, 
one-way ANOVA followed by the Bonferroni test. The dotted lines represent no 
significant difference between the two groups. Error bars represent the mean ± SEM. 
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There is a linear dose-response from 10-7 to 10-10 mol/L RA. The RA concentration of
the sample is within the linear section of the standard curve. R2 represents the
coefficient of determination for linear regression analysis.
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Supplementary Figure 2. RA was stable at 37°C for 24 h. RA was added to the
culture medium at a concentration of 10 nmol/L. The medium was either immediately
frozen and stored at -80°C (n = 4) or incubated at 37°C for 24 h in a 5% CO2 incubator
(n = 4). The RA concentrations of the two groups of samples were then determined by
the RA reporter cell line. There was no significant degradation of RA in the sample
that had been incubated at 37°C for 24 h in comparison to the immediately frozen
sample.
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Supplementary Figure 3. No significant difference in the protein content of the
tailbuds excised from embryos of ND and MD mice. Total protein in individual
tailbuds measured using Bradford assay (n = 18-20 from three litters). Error bars
represent the mean ± SEM.
Supplementary Figure 4. The midbrain, which does not express any of the three
Cyp26 genes, exhibits no difference in RA levels between embryos of MD and ND
mice after RA treatment. A: Whole-mount in situ hybridization patterns showed that
all three Cyp26 genes (Cyp26a1, Cyp26b1, and Cyp26c1) did not express in the
midbrain (MB) of E9 embryos of mice with or without (No RA) treatment of 50
mg/kg RA (50RA). Scale bar = 0.4 mm. B: Amount of RA in the tailbud and midbrain
of E9 embryos 3 h after injection of 50RA, measured using high-performance liquid
chromatography (n = 7 for ND and 9 for MD from seven and nine litters, respectively).
The tailbud of embryos of MD mice with reduced Cyp26a1 expression had a
significantly greater amount of RA than that in embryos of ND mice. In contrast, the
midbrain, without Cyp26 expression, showed no difference in the amount of RA
between embryos of MD and ND mice. *P < 0.001, Student t test. Error bars represent
the mean ± SEM.
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Supplementary Figure 5. Heterozygosity for Cyp26a1 loss-of-function exacerbates
increased susceptibility to RA-induced caudal truncation in embryos exposed to
diabetes. Morphology of the caudal region of E13 Cyp26a1 heterozygous null (+/-)
embryos and their wild-type (+/+) littermates from ND and MD mice challenged with
25 mg/kg RA (25RA) or vehicle as control (CON) at E9. Embryos of different
genotype-maternal environment combinations showed prominent differences in
susceptibility to RA-induced caudal truncation. Scale bar = 0.1 cm.
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Supplementary Figure 6. Oral feeding of low-dose RA does not cause any change in
expression of key genes for caudal development. Quantification of mRNA levels of
various caudal regulatory genes, normalized to β-actin, and expressed relative to ND
(CON), which was set as 1, in the tailbuds of E9 embryos from ND and MD mice 2 h
after oral feeding with low-dose RA (0.625 mg/kg RA [0.625RA]) or with vehicle as
the control (CON) (n = 5 from 5 litters). No significant changes in mRNA levels were
associated with low-dose RA treatment. *P < 0.05, one-way ANOVA followed by the
Bonferroni test. Error bars represent the mean ± SEM.
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Supplementary Figure 7. Incidence of exencephaly in E13 embryos (ICR X ICR
genetic background) from ND and MD mice with or without (No RA) in vivo
challenge with 25 mg/kg RA (25RA) at E8 (n = 9-12 litters). In untreated conditions,
only 3% of embryos of MD mice developed exencephaly. However, when challenged
with 25RA, a dose that only induced exencephaly in 3% of embryos of ND mice,
embryos of MD mice were significantly more susceptible to RA teratogenesis and
exhibited a ninefold increase in the incidence rate of exencephaly. *P < 0.001, one-
way ANOVA followed by the Bonferroni test. Error bars represent the mean ± SEM.
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Supplementary Table 1. Blood glucose levels of ND and MD mice before pregnancy and on 
the day of embryo collection 
 
   
 
ND 
Before 
pregnancy 
ND 
Day of embryo 
collection (E9) 
MD 
Before 
pregnancy 
MD 
Day of embryo  
Collection (E9) 
Blood glucose 
levels (mmol/L) 
mean ± SEM 
Not determined 
 
6.08 ± 0.12 
(n = 12 ) 
21.56 ± 0.32 
(n = 101) 
27.53 ± 0.51* 
(n = 67) 
 
Remarks: 
The blood glucose levels of MD mice on the day of embryo collection at E9 were significantly 
higher than that of MD mice before pregnancy (*P < 0.001, Student t test), with none of them 
having blood glucose levels lower than 16.7 mmol/L. Similarly, there were hardly any MD mice 
exhibiting blood glucose levels lower than 16.7 mmol/L on the day of embryo collection at other 
stages (E8, E13 and E18). These findings supported that embryos of MD mice were exposed to a 
hyperglycemic milieu throughout development. 
 
  
Supplementary Table 2. PCR conditions and primer sequences 
The PCR conditions included initiation at 95oC for 10 min, followed by 40 cycles comprising of 
denaturation at 95°C for 15 sec, annealing at 55°C for 30 sec and extension at 72°C for another 
30 sec. Primers sequences, designed by Primer Express Software (Applied Biosystems), for 
detecting various mouse genes were:  
 
 
Gene Primer Sequences 
β-actin forward: 5’-TGT TAC CAA CTG GGA CGA CA-3’  
reverse: 5’-GGG GTG TTG AAG GTC TCA AA-3’  
Cdx2 forward: 5’-AAA CTC CAC TGT CAC CCA GT-3’ 
reverse: 5’-CCT GAG GTC CAT AAT TCC AC-3’ 
Cyp26a1 forward: 5’-CAG TGC TAC CTG CTC GTG AT-3’  
reverse: 5’-AGA GAA GAG ATT GCG GGT CA-3’ 
Cyp26b1 forward: 5’-TTC AGT GAG GCA AGA AGA CA-3’ 
reverse: 5’-CTG GGA GGA GGT GCT AAG TA-3’ 
Cyp26c1 forward: 5’-GGG ACC AGT TGT ATG AGC AC-3’ 
reverse: 5’-AGC CAA CTC CTT CAG CTC TT-3’ 
Fgf8 forward: 5’-AGA GAT CGT GCT GGA GAA CA-3’  
reverse: 5’-AAG GGC GGG TAG TTG AGG AA-3’ 
Rarγ forward: 5’-AGG CAG CAG ACT GAC CAT TT-3’ 
reverse: 5’-TTC TGG TAG GTG TGC AGC AG-3’ 
Rxrα forward: 5’-TCA CCA TCC TCG CCA TCT TT-3’ 
reverse: 5’-CTC CAA ACA GAG GTG CCA TG-3’ 
Wnt3a forward: 5’-CTG GCA GCT GTG AAG TGA AG-3’  
reverse: 5’-GCC TCG TAG TAG ACC AGG TC-3’ 
 
  
Supplementary Table 3. The amount of RA in individual tailbuds of embryos of ND and MD 
mice 3 h after injection of 50 mg/kg RA at E9, measured using the RA reporter cell line or 
high-performance liquid chromatography (HPLC) 
 
 
 
 Amount of RA per tailbud (nmol/L) 
 ND MD Difference between ND and MD 
RA reporter cell line 4.21  0.13   (n = 36)* 
6.71  0.20  
 (n = 42)* 59.38% 
HPLC 7.88  0.62    (n = 7)** 
12.80  0.79  
  (n = 9)** 62.44% 
 
 
* One tailbud in each sample 
 
** Tailbuds from one litter of embryos were pooled as one sample 
 
 
Remarks: 
The data for the RA reporter cell line was extracted from Fig. 2B.  
The HPLC experiment was conducted in a separate study to validate the result in Fig. 2B. 
In analyzing the result, it is more relevant to compare the difference between ND and MD 
groups using the two RA detection methods, rather than the absolute amount of RA in the 
tailbud. 
 
 
 
 
 
 
